Anti-c-PLA2 (Phospho-Ser505) polyclonal Antibody detects c-PLA2 only when phosphorylated at Ser505. Validated for WB, IHC, IF and ELISA. Reactive for Human, Mouse, Rat. AssayBiotechnology an original antibody manufacturer.
Details
-
Product Name
c-PLA2 (Phospho-Ser505) Antibody
-
Catalog No
A0065
-
Storage/Stability
Stable at -20°C for at least 1 year.
-
Applications
WB, IHC, IF, ELISA
-
Clonality
Polyclonal
-
Host Species
Rabbit
-
Reactivity
Human, Mouse, Rat
-
Application Dilutions
WB: 1:500~1:1000 IHC: 1:50~1:100 IF: 1:100~1:500 ELISA: 1:10000
-
Database Links
Gene ID: 5321, Swiss-Prot #: P47712, OMIM #: 600522, Unigene #: Hs.497200
-
Immunogen
The antiserum was produced against synthesized peptide derived from human c-PLA2 around the phosphorylation site of Ser505.
-
Immunogen Range
471-520
-
Modification Sites
H: S505 M: S505 R: S505
-
MW
85 kDa
-
NCBI Gene Symbol
PLA2G4A
-
Physical Form
Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
-
Purification
The antibody was purified from rabbit antiserum by affinity-chromatography using phospho peptide. The antibody against non-phospho peptide was removed by chromatography using corresponding non-phospho peptide.
-
Specificity
c-PLA2 (Phospho-Ser505) Antibody detects endogenous levels of c-PLA2 only when phosphorylated at Ser505.
-
Synonyms
CPLA2, Cytosolic phospholipase A2, PA24, PA24A, PLA2G4, PLA2G4A, Phosphatidylcholine 2-acylhydrolase
-
Target Modification
Phospho
Application Images
Western blot analysis of lysates from HeLa cells treated with TNF-a 20ng/ml 30', using c-PLA2 (Phospho-Ser505) Antibody. The lane on the right is blocked with the phospho peptide.
Immunohistochemistry analysis of paraffin-embedded human colon carcinoma, using c-PLA2 (Phospho-Ser505) Antibody. The picture on the right is blocked with the phospho peptide.
Immunofluorescence analysis of HeLa cells treated with TNF-a 20nM 15', using c-PLA2 (Phospho-Ser505) Antibody. The picture on the right is blocked with the phospho peptide.
Western blot analysis of VEC using p-cPLA2 (S505) antibody. Antibody was diluted at 1:1000
Immunohistochemical analysis of paraffin-embedded Human breast cancer. Antibody was diluted at 1:100(4°,ON). Negative control (right) obtaned from antibody was pre-absorbed by immunogen peptide.
|
Western blot analysis of lysates from HeLa cells treated with TNF-a 20ng/ml 30', using c-PLA2 (Phospho-Ser505) Antibody. The lane on the right is blocked with the phospho peptide. |
|
Immunohistochemistry analysis of paraffin-embedded human colon carcinoma, using c-PLA2 (Phospho-Ser505) Antibody. The picture on the right is blocked with the phospho peptide. |
|
Immunofluorescence analysis of HeLa cells treated with TNF-a 20nM 15', using c-PLA2 (Phospho-Ser505) Antibody. The picture on the right is blocked with the phospho peptide. |
|
Western blot analysis of VEC using p-cPLA2 (S505) antibody. Antibody was diluted at 1:1000 |
|
Immunohistochemical analysis of paraffin-embedded Human breast cancer. Antibody was diluted at 1:100(4°,ON). Negative control (right) obtaned from antibody was pre-absorbed by immunogen peptide. |